The rs2233678 Polymorphism in PIN1 Promoter Region Reduced Cancer Risk: A Meta-Analysis

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Li, Qi ^a   Dong, Zhao ^b   Lin, Yun ^c   Jia, Xinyan ^c   Li, Qun ^c   Jiang, Hong ^c   Wang, Liwei ^a   Gao, Yong ^c  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b No 85 Hospital of PLA   (China)

^c TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDYLPROLYL ISOMERASE PIN1;

ALLELE; ARTICLE; CANCER RISK; CONFIDENCE INTERVAL; DNA POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; META ANALYSIS (TOPIC); PROMOTER REGION; PUBLISHING; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK REDUCTION; STATISTICAL ANALYSIS;

ALLELES; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; NEOPLASMS; ODDS RATIO; PEPTIDYLPROLYL ISOMERASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PUBLICATION BIAS; RISK;

EID: 84879893112     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068148     Document Type: Article

References (31)

1. Lu KP, (2003) Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics. Cancer Cell 4: 175-180.
2. Lu KP, (2004) Pinning down cell signaling, cancer and Alzheimer's disease. Trends Biochem Sci 29: 200-209.
3. Ranganathan R, Lu KP, Hunter T, Noel JP, (1997) Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell 89: 875-886.
4. Lu KP, Hanes SD, Hunter T, (1996) A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 380: 544-547.
5. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, et al. (2001) Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 20: 3459-3472.
6. Lam PB, Burga LN, Wu BP, Hofstatter EW, Lu KP, et al. (2008) Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. Mol Cancer 7: 91.
7. Ayala G, Wang D, Wulf G, Frolov A, Li R, et al. (2003) The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res 63: 6244-6251.
8. Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP, (2001) Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol 3: 793-801.
9. Cao W, Ruan H, Tang H, Ling P, (2012) Association between polymorphisms in prolyl isomerase Pin1 and the risk for laryngeal squamous cell carcinoma. Jiangsu Medical Journal 38: 1067-1070.
10. Han CH, Lu J, Wei Q, Bondy ML, Brewster AM, et al. (2010) The functional promoter polymorphism (-842 G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger. Breast Cancer Res Treat 122: 243-249.
11. Lu J, Hu Z, Wei S, Wang LE, Liu Z, et al. (2009) A novel functional variant (-842 G>C) in the PIN1 promoter contributes to decreased risk of squamous cell carcinoma of the head and neck by diminishing the promoter activity. Carcinogenesis 30: 1717-1721.
12. Lu J, Yang L, Zhao H, Liu B, Li Y, et al. (2011) The polymorphism and haplotypes of PIN1 gene are associated with the risk of lung cancer in Southern and Eastern Chinese populations. Hum Mutat 32: 1299-1308.
13. Lu Y, Huang GL, Pu XX, He YX, Li BB, et al. (2012) Association between PIN1 promoter polymorphisms and risk of nasopharyngeal carcinoma. Mol Biol Rep 40: 3777-3782.
14. Naidu R, Har YC, Taib NA, (2011) Analysis of peptidyl-propyl-cis/trans isomerase 1 (PIN1) gene -842(G>C) and -667(T>C) polymorphic variants in relation to breast cancer risk and clinico-pathological parameters. Scand J Clin Lab Invest 71: 500-506.
15. Segat L, Milanese M, Crovella S (2007) Pin1 promoter polymorphisms in hepatocellular carcinoma patients. Gastroenterology 132: 2618-2619; author reply 2619-2620.
16. You Y, Deng J, Zheng J, Jiang L, Li N, et al. (2013) Functional polymorphisms in PIN1 promoter and esophageal carcinoma susceptibility in Chinese population. Mol Biol Rep 40: 829-838.
17. Galat A, (2003) Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity-targets-functions. Curr Top Med Chem 3: 1315-1347.
18. Lu KP, Suizu F, Zhou XZ, Finn G, Lam P, et al. (2006) Targeting carcinogenesis: a role for the prolyl isomerase Pin1? Mol Carcinog 45: 397-402.
19. Lu KP, Zhou XZ, (2007) The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 8: 904-916.
20. Miyashita H, Mori S, Motegi K, Fukumoto M, Uchida T, (2003) Pin1 is overexpressed in oral squamous cell carcinoma and its levels correlate with cyclin D1 overexpression. Oncol Rep 10: 455-461.
21. Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, et al. (1997) Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 278: 1957-1960.
22. Pathan N, Aime-Sempe C, Kitada S, Basu A, Haldar S, et al. (2001) Microtubule-targeting drugs induce bcl-2 phosphorylation and association with Pin1. Neoplasia 3: 550-559.
23. Shen M, Stukenberg PT, Kirschner MW, Lu KP, (1998) The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes Dev 12: 706-720.
24. Liu W, Youn HD, Zhou XZ, Lu KP, Liu JO, (2001) Binding and regulation of the transcription factor NFAT by the peptidyl prolyl cis-trans isomerase Pin1. FEBS Lett 496: 105-108.
25. Messenger MM, Saulnier RB, Gilchrist AD, Diamond P, Gorbsky GJ, et al. (2002) Interactions between protein kinase CK2 and Pin1. Evidence for phosphorylation-dependent interactions. J Biol Chem 277: 23054-23064.
26. Wulf G, Finn G, Suizu F, Lu KP, (2005) Phosphorylation-specific prolyl isomerization: is there an underlying theme? Nat Cell Biol 7: 435-441.
27. Segat L, Pontillo A, Annoni G, Trabattoni D, Vergani C, et al. (2007) PIN1 promoter polymorphisms are associated with Alzheimer's disease. Neurobiol Aging 28: 69-74.
28. Lau J, Ioannidis JP, Schmid CH, (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820-826.
29. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
30. Whitehead A, Whitehead J, (1991) A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 10: 1665-1677.
31. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.